New jersey

Index
Globenewswire

Synchronoss Unveils Capsyl Cloud at MWC Barcelona – A Turn-Key Personal Cloud Solution for Global Operators

Globenewswire

Horizon Group USA Names Big Wheel Toys as Australian Distributor

Globenewswire

Synchronoss Technologies Mengumumkan Tanggal Panggilan Konferensi Laporan Pendapatan Kuartal Keempat dan Tahun Penuh 2024

Globenewswire

Synchronoss Technologies Announces Fourth Quarter and Full Year 2024 Earnings Call Date

Globenewswire

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

Globenewswire

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

Globenewswire

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

Globenewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

Globenewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

Globenewswire

Verisk Wildfire Model is the First Catastrophe Model Under Review for Insurance Ratemaking in the State of California

Globenewswire

New BASF VOC2.0™ Catalyst Technology Now Available in the VOZC™ Converter on Airbus A320 Fleet

Globenewswire

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Globenewswire

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Globenewswire

BASF Environmental Catalyst and Metal Solutions meraih Penghargaan Paten Edison 2024

Globenewswire

BASF Environmental Catalyst and Metal Solutions wins 2024 Edison Patent Award

Globenewswire

Horizon Group USA Accelerates Global Growth Strategy with Expanded Leadership

Globenewswire

Synchronoss Memperpanjang Kemitraan dengan Operator Utama Prancis

Globenewswire

Synchronoss Renews Partnership with Major French Operator

Globenewswire

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Globenewswire

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as Well as

Globenewswire

ORBCOMM Launches First Native Satellite Tracker for Advanced OGx Network

Globenewswire

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Globenewswire

Orbcomm Joins Move to -15°C Coalition to Promote Cold Chain Sustainability

Globenewswire

Verisk Welcomes Greg Hendrick to Its Board of Directors